A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Tinostamustine (Primary)
  • Indications Breast cancer; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 10 Oct 2017 According to a Mundipharma media release, this trial is being conducted at the Stanford University, Cedars Sinai Medical Center (Los Angeles) and The Mayo Clinic (Scottsdale).
    • 10 Oct 2017 Status changed from planning to recruiting, according to a Mundipharma media release.
    • 31 Jul 2015 According to the media release of the Mundipharma EDO GmbH, the company was granted INDA approval form FDA for its first anti-cancer compound EDO-S101 indicated for the treatment of relapsed/refractory haematologic malignancies and solid tumours and plans to develop this study in 2015 once the dose escalation part of the first in human study has been completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top